A prospective study of fatty liver index and incident hypertension: The KoGES-ARIRANG study

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Huh, Ji Hye ^a   Ahn, Song Vogue ^a   Koh, Sang Baek ^a   Choi, Eunhee ^a   Kim, Jang Young ^b   Sung, Ki Chul ^c   Kim, Eung Ju ^d   Park, Jeong Bae ^e  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University Wonju   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Kwandong University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALBUMIN; C REACTIVE PROTEIN; CREATININE;

ADULT; AGED; ALBUMIN URINE LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; FATTY LIVER; FATTY LIVER INDEX; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; URINE LEVEL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84957584837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143560     Document Type: Article

References (39)

1. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: Implications for therapy. Hypertension. 2004; 44(5): 595-601. doi: 10.1161/01.HYP.0000145180.38707.84 PMID: 15452024.
2. Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Ninomiya, Algert, Arima H, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. Bmj. 2008; 336(7653): 1121-3. doi: 10.1136/bmj.39548. 738368.BE PMID: 18480116; PubMed Central PMCID: PMC2386598.
3. Harrison W, Marshall T. The epidemiology of blood pressure in East Asia. Journal of human hypertension. 2006; 20(2): 97-9. doi: 10.1038/sj.jhh.1001958 PMID: 16251999.
4. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 2005; 42(1): 44-52. doi: 10.1002/hep.20734 PMID: 15895401.
5. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of hepatology. 2008; 49(4): 608-12. doi: 10.1016/j.jhep.2008.06.018 PMID: 18682312.
6. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for nonalcoholic fatty liver disease. Arquivos de gastroenterologia. 2012; 49(1): 89-96. PMID: 22481692.
7. Lopez-Suarez A, Guerrero JM, Elvira-Gonzalez J, Beltran-Robles M, Canas-Hormigo F, Bascunana- Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. European journal of gastroenterology & hepatology. 2011; 23(11): 1011-7. doi: 10.1097/MEG. 0b013e32834b8d52 PMID: 21915061.
8. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. Journal of hypertension. 2010; 28(9): 1829-35. doi: 10.1097/HJH.0b013e32833c211b PMID: 20577126.
9. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995; 36(3): 437-41. PMID: 7698705; PubMed Central PMCID: PMC1382461.
10. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. British medical journal. 1986; 292(6512): 13-5. PMID: 3080046; PubMed Central PMCID: PMC1338970.
11. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. Journal of clinical ultrasound: JCU. 1996; 24(1): 25-9. doi: 10.1002/ (SICI)1097-0096(199601)24: 13.0.CO;2-N PMID: 8655663.
12. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC gastroenterology. 2006; 6: 33. doi: 10.1186/1471-230X-6-33 PMID: 17081293; PubMed Central PMCID: PMC1636651.
13. Kim JH, Kwon SY, Lee SW, Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver international: Official journal of the International Association for the Study of the Liver. 2011; 31(10): 1600-1. doi: 10.1111/j.1478-3231.2011.02580.x PMID: 22093336.
14. Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World journal of gastroenterology: WJG. 2013; 19(1): 57-64. doi: 10.3748/wjg.v19.i1.57 PMID: 23326163; PubMed Central PMCID: PMC3542754.
15. Jung CH, Lee WJ, Hwang JY, Yu JH, Shin MS, Lee MJ, et al. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. Diabetic medicine: A journal of the British Diabetic Association. 2013; 30(4): 428-35. doi: 10.1111/dme.12104 PMID: 23278318.
16. Kim JY, Ahn SV, Yoon JH, Koh SB, Yoon J, Yoo BS, et al. Prospective study of serum adiponectin and incident metabolic syndrome: The ARIRANG study. Diabetes care. 2013; 36(6): 1547-53. doi: 10.2337/ dc12-0223 PMID: 23275369; PubMed Central PMCID: PMC3661834.
17. Jung DH, Kim JY, Kim JK, Koh SB, Park JK, Ahn SV. Relative contribution of obesity and serum adiponectin to the development of hypertension. Diabetes research and clinical practice. 2014; 103(1): 51-6. doi: 10.1016/j.diabres.2013.09.018 PMID: 24398319.
18. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence- based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014; 311(5): 507-20. doi: 10.1001/jama.2013.284427 PMID: 24352797.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-9. PMID: 3899825.
20. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The New England journal of medicine. 2010; 363(14): 1341-50. doi: 10.1056/NEJMra0912063 PMID: 20879883.
21. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care Atherosclerosis. 2013; 230(2): 258-67. doi: 10.1016/j.atherosclerosis.2013.07.052 PMID: 24075754.
22. Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. Journal of hypertension. 2015; 33(6): 1207-14. doi: 10.1097/HJH.0000000000000532 PMID: 25693058.
23. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. Journal of gastroenterology and hepatology. 2014; 29(11): 1926-31. doi: 10.1111/jgh.12643 PMID: 24910023.
24. Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Experimental biology and medicine. 2011; 236(5): 557-66. doi: 10.1258/ebm.2011.010375 PMID: 21508249.
25. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World journal of hepatology. 2012; 4(12): 327-31. doi: 10.4254/wjh.v4.i12.327 PMID: 23355909; PubMed Central PMCID: PMC3554795.
26. Kato J, Koda M, Kishina M, Tokunaga S, Matono T, Sugihara T, et al. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. International journal of molecular medicine. 2012; 30(1): 107-13. doi: 10.3892/ijmm.2012.958 PMID: 22469867.
27. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007; 45(6): 1375-81. doi: 10. 1002/hep.21638 PMID: 17518368.
28. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. Journal of gastroenterology and hepatology. 2007; 22(7): 1086-91. doi: 10.1111/j.1440-1746.2006.04781.x PMID: 17608855.
29. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: Potential links with inflammation. International journal of obesity and related metabolic disorders: Journal of the International Association for the Study of Obesity. 2003; 27 Suppl 3: S6-11. doi: 10.1038/sj.ijo.0802491 PMID: 14704736.
30. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature medicine. 2005; 11(2): 183-90. doi: 10.1038/nm1166 PMID: 15685173; PubMed Central PMCID: PMC1440292.
31. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American journal of physiology Endocrinology and metabolism. 2001; 280(5): E745-51. PMID: 11287357.
32. Bhagat B, Burke WJ, Dhalla NS. Insulin-induced enhancement of uptake of noradrenaline in atrial strips. British journal of pharmacology. 1981; 74(2): 325-32. PMID: 6274461; PubMed Central PMCID: PMC2071738.
33. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, et al. Pathophysiological role of leptin in obesity-related hypertension. The Journal of clinical investigation. 2000; 105(9): 1243-52. doi: 10. 1172/JCI8341 PMID: 10791999; PubMed Central PMCID: PMC315441.
34. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. Journal of hypertension. 2006; 24(5): 789-801. doi: 10.1097/01.hjh.0000222743.06584.66 PMID: 16612235.
35. Rojas E, Rodriguez-Molina D, Bolli P, Israili ZH, Faria J, Fidilio E, et al. The role of adiponectin in endothelial dysfunction and hypertension. Current hypertension reports. 2014; 16(8): 463. doi: 10.1007/ s11906-014-0463-7 PMID: 24924994.
36. Yoo HJ, Choi KM. Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes & metabolism journal. 2015; 39(1): 10-5. doi: 10.4093/dmj.2015.39.1.10 PMID: 25729707; PubMed Central PMCID: PMC4342531.
37. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3): 745-50. PMID: 12198701.
38. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). Journal of hepatology. 2015; 63(2): 486-93. doi: 10.1016/j.jhep.2015.02.051 PMID: 25772036.
39. Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gammaglutamyltransferase, and early carotid plaques. Hepatology. 2012; 55(5): 1406-15. doi: 10.1002/hep. 25555 PMID: 22334565.